(CIT): Skeletal Complications of Malignancy will address the pathophysiology of the special forms of bone disease that occur in breast cancer, prostate cancer and multiple myeloma and the role of the bone marrow microenvironment in supporting bone metastases. Recent data show significant new information on the molecular mechanisms responsible for the effects of these different malignancies on the skeleton, and are providing novel and exciting potential targets for innovative drug therapies. These new findings will be presented by the international experts with updates on preclinical and clinical studies of currently utilized therapeutic agents. The symposium is designed for basic scientists and clinicians with interest in oncology, urology, hematology, and bone metabolism.